H.C. Wainwright raised the firm’s price target on uniQure (QURE) to $110 from $70 and keeps a Neutral rating on the shares. The firm says AMT-130’s pivotal three-year dataset establishes a new benchmark in Huntington’s disease. The data show “robust” clinical efficacy, biomarker validation, and a durable safety profile that support a Q1 of 2026 biologics license application filing and potential U.S. launch in 2026, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QURE: